{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:06:30Z","timestamp":1790877990522,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12931-019-1134-7","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T09:02:59Z","timestamp":1564477379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight\/body mass index: meta-analysis of MENSA and MUSCA"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7039-4621","authenticated-orcid":false,"given":"Frank C.","family":"Albers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Taill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Bratton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Yancey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namhee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"1134_CR1","unstructured":"Global asthma report. \n                              http:\/\/globalasthmareport.org\/\n                              \n                           . Accessed 16 Oct 2018."},{"key":"1134_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343\u201373.","journal-title":"Eur Respir J"},{"key":"1134_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1365-2222.2011.03929.x","volume":"42","author":"S Wenzel","year":"2012","unstructured":"Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012;42:650\u20138.","journal-title":"Clin Exp Allergy"},{"key":"1134_CR4","unstructured":"Mepolizumab (NUCALA) US prescribing information. \n                              https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125526Orig1s000Lbl.pdf\n                              \n                           . Accessed 4 Dec 2018."},{"key":"1134_CR5","unstructured":"Mepolizumab (NUCALA) EU summary of product characteristics. \n                              https:\/\/www.ema.europa.eu\/documents\/product-information\/nucala-epar-product-information_en.pdf\n                              \n                           . Accessed 4 Dec 2018."},{"key":"1134_CR6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189\u201397.","journal-title":"N Engl J Med"},{"key":"1134_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","volume":"5","author":"GL Chupp","year":"2017","unstructured":"Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390\u2013400.","journal-title":"Lancet Respir Med"},{"key":"1134_CR8","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198\u2013207.","journal-title":"N Engl J Med"},{"key":"1134_CR9","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1634\/theoncologist.2017-0167","volume":"22","author":"J Hendrikx","year":"2017","unstructured":"Hendrikx J, Haanen J, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22:1212\u201321.","journal-title":"Oncologist"},{"key":"1134_CR10","doi-asserted-by":"publisher","unstructured":"Garcia-Rio F, Alvarez-Puebla MJ, De Esteban I, Barranco P, Olaguibel JM. Obesity and asthma. Key clinical questions. J Investig Allergol Clin Immunol. 2018;29. \n                              https:\/\/doi.org\/10.18176\/jiaci.0316\n                              \n                           .","DOI":"10.18176\/jiaci.0316"},{"key":"1134_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17425255.2018.1440287","volume":"14","author":"C Smit","year":"2018","unstructured":"Smit C, De Hoogd S, Bruggemann RJM, Knibbe CAJ. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol. 2018;14:275\u201385.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1134_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1183\/09031936.02.00063702","volume":"19","author":"PW Jones","year":"2002","unstructured":"Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19:398\u2013404.","journal-title":"Eur Respir J"},{"key":"1134_CR13","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.jaci.2011.12.980","volume":"129","author":"MM Cloutier","year":"2012","unstructured":"Cloutier MM, Schatz M, Castro M, Clark N, Kelly HW, Mangione-Smith R, Sheller J, Sorkness C, Stoloff S, Gergen P. Asthma outcomes: composite scores of asthma control. J Allergy Clin Immunol. 2012;129:S24\u201333.","journal-title":"J Allergy Clin Immunol"},{"key":"1134_CR14","unstructured":"GSK Clinical Studies Register. \n                              https:\/\/www.gsk-studyregister.com\/study\/6079\n                              \n                           . Accessed 19 July 2019."},{"key":"1134_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejim.2018.01.026","volume":"52","author":"B Sposato","year":"2018","unstructured":"Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Latorre M, Scichilone N, Matucci A, Vultaggio A, Ricci A, et al. Factors reducing omalizumab response in severe asthma. Eur J Intern Med. 2018;52:78\u201385.","journal-title":"Eur J Intern Med"},{"key":"1134_CR16","first-page":"A2490","volume":"197","author":"F Trudo","year":"2018","unstructured":"Trudo F, Hirsch I, Gopalan G, Martin U. Impact of body mass index on efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma: pooled analysis of the SIROCCO and CALIMA trials. Am J Respir Crit Care Med. 2018;197:A2490.","journal-title":"Am J Respir Crit Care Med"},{"key":"1134_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651\u20139.","journal-title":"Lancet"},{"key":"1134_CR18","first-page":"81","volume":"11","author":"P Haldar","year":"2017","unstructured":"Haldar P. Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma. Biologics. 2017;11:81\u201395.","journal-title":"Biologics"},{"key":"1134_CR19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1513\/AnnalsATS.201312-454OC","volume":"11","author":"H Ortega","year":"2014","unstructured":"Ortega H, Li H, Suruki R, Albers F, Gordon D, Yancey S. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc. 2014;11:1011\u20137.","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"1134_CR20","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.anai.2017.09.072","volume":"119","author":"H. Ortega","year":"2017","unstructured":"Ortega H, Albers F, Llanos-Ackert J, Bradford E, Price R, Pouliquen I, Castro M. P506. Impact of weight on the efficacy of mepolizumab in patients with severe eosinophilic asthma. Ann Allergy Asthma Immunol. 2017;119:e3\u20134.","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"1134_CR21","doi-asserted-by":"publisher","unstructured":"Chia YL, Yan L, Yu B, Wang B, Barker P, Goldman M, Roskos L. Relationship between benralizumab exposure and efficacy for patients with severe eosinophilic asthma. Clin Pharmacol Ther. 2019. \n                              https:\/\/doi.org\/10.1002\/cpt.1371\n                              \n                           .","DOI":"10.1002\/cpt.1371"},{"key":"1134_CR22","first-page":"538642","volume":"2013","author":"S Novosad","year":"2013","unstructured":"Novosad S, Khan S, Wolfe B, Khan A. Role of obesity in asthma control, the obesity-asthma phenotype. J Allergy (Cairo). 2013;2013:538642.","journal-title":"J Allergy (Cairo)"},{"key":"1134_CR23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1164\/rccm.201208-1470OC","volume":"188","author":"D Desai","year":"2013","unstructured":"Desai D, Newby C, Symon FA, Haldar P, Shah S, Gupta S, Bafadhel M, Singapuri A, Siddiqui S, Woods J, et al. Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma. Am J Respir Crit Care Med. 2013;188:657\u201363.","journal-title":"Am J Respir Crit Care Med"},{"key":"1134_CR24","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1183\/09031936.00139810","volume":"38","author":"HA Scott","year":"2011","unstructured":"Scott HA, Gibson PG, Garg ML, Wood LG. Airway inflammation is augmented by obesity and fatty acids in asthma. Eur Respir J. 2011;38:594\u2013602.","journal-title":"Eur Respir J"},{"key":"1134_CR25","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.jaci.2017.04.047","volume":"141","author":"N Lugogo","year":"2018","unstructured":"Lugogo N, Green CL, Agada N, Zhang S, Meghdadpour S, Zhou R, Yang S, Anstrom KJ, Israel E, Martin R, et al. Obesity's effect on asthma extends to diagnostic criteria. J Allergy Clin Immunol. 2018;141:1096\u2013104.","journal-title":"J Allergy Clin Immunol"},{"key":"1134_CR26","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633\u201359.","journal-title":"Clin Pharmacokinet"},{"key":"1134_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.yrtph.2014.12.002","volume":"71","author":"PJ Lowe","year":"2015","unstructured":"Lowe PJ, Georgiou P, Canvin J. Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE. Regul Toxicol Pharmacol. 2015;71:68\u201377.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1134_CR28","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.5414\/CP202446","volume":"53","author":"IJ Pouliquen","year":"2015","unstructured":"Pouliquen IJ, Kornmann O, Barton SV, Price JA, Ortega HG. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53:1015\u201327.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1134_CR29","unstructured":"Reslizumab (CINQAIR) US prescribing information. \n                              https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761033lbl.pdf\n                              \n                           . Accessed 21 Mar 2019."}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1134-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-019-1134-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1134-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T23:06:22Z","timestamp":1595977582000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-019-1134-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,30]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1134"],"URL":"https:\/\/doi.org\/10.1186\/s12931-019-1134-7","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,30]]},"assertion":[{"value":"14 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients provided written informed consent for MENSA and MUSCA. The original MENSA and MUSCA study protocols (on which this analysis was based) were approved by local or national research ethics committees. Both MENSA and MUSCA were conducted in accordance with the ethical principles of the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines, and the applicable country-specific regulatory requirements.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DJB, ESB, SWY and NK are employees of GSK and hold stocks\/shares in GSK. FCA was an employee of GSK at the time of this analysis and holds stocks\/shares in GSK. AP has received grants, personal fees and non-financial support and other from AstraZeneca, Teva, Mundipharma, GSK, Chiesi and Boehringer Ingelheim; has received personal fees and non-financial support from Novartis, Menarini and Zambon; and has received grants from Sanofi. CT has received fees from GSK, AstraZeneca, Novartis, Teva, Sanofi, Genzyme and Roche (consultancy, advisory boards) and was an investigator in trials involving GSK, AstraZeneca, Novartis, Sanofi, Roche and Boehringer Ingelheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}